Proposal for KN-93

Overview of Therapeutic Candidate:
KN-93 is a fully synthetic small-molecule drug that was originally developed as a research tool for selectively inhibiting calcium/calmodulin-dependent protein kinase II (CaMKII). It belongs to a class of sulfonamide derivatives designed to antagonize the calmodulin (CaM) binding process that is essential for CaMKII activation. The molecule’s chemical structure, described as N-[2-[[[3-(4′-chlorophenyl)-2-propenyl]-methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4′-methoxybenzenesulfonamide phosphate, identifies it as belonging to the arylsulfonamide and isoquinoline-sulfonamide family (Brzozowski & Skelding, 2019, pp. 16–17; Franchini et al., 2010, pp. 1–2). Synthetic methodologies have evolved for KN-93; for example, microwave-assisted reductive amination strategies have improved the efficiency and yield of its production (Franchini et al., 2010, pp. 4–5). Historically, KN-93 was discovered during the early phases of CaMKII inhibitor development, arising from efforts to generate compounds that could modulate intracellular calcium signaling by targeting the calmodulin-dependent activation step rather than competing at the ATP-binding site. This specific mechanism of action places KN-93 in a category of allosteric inhibitors that, rather than occupying the enzyme’s catalytic pocket, block the conformational transition necessary for activation by binding to the Ca2+/CaM complex (Wong et al., 2019, pp. 1–3; Pellicena & Schulman, 2014, pp. 2–3). In addition to its established use in cardiovascular and neurological research, KN-93 represents an important prototype for repurposing studies because its robust cell permeability and well-characterized inhibitory properties provide a solid foundation for exploring new therapeutic indications such as sarcopenia.

Therapeutic History:
KN-93 has a long history in preclinical pharmacological research, primarily as a tool to dissect the role of CaMKII in various pathological and physiological processes. In cardiac studies, KN-93 has been instrumental in revealing that CaMKII hyperactivity contributes to pathological phosphorylation events associated with heart failure, arrhythmogenesis, and defective calcium handling (Sossalla et al., 2010, pp. 7–9; Beauverger et al., 2020). It has also been extensively used in studies of neuronal signaling and synaptic plasticity, where its ability to inhibit CaMKII modulates processes such as long-term potentiation and synaptic tagging (Redondo et al., 2010, pp. 3–4; Pellicena & Schulman, 2014, pp. 9–10). In oncology research, KN-93 has been explored in various cancer cell lines, where its off-target effects—such as inhibition of voltage-gated ion channels—were noted alongside its primary CaMKII-inhibitory function (Brzozowski & Skelding, 2019, pp. 26–28). Importantly, a search of clinical trial registries for “KN-93 OR CaMKII inhibitor AND (sarcopenia OR muscle wasting OR aging OR skeletal muscle)” returned no registered clinical trials, indicating that KN-93’s utility has not previously been evaluated in human studies for sarcopenia or related muscle wasting conditions (ClinicalTrials.gov, n.d.). In the context of muscle biology, preclinical paradigms have begun to validate the role of CaMKII and its downstream target, the ryanodine receptor type 1 (RyR1), in skeletal muscle function and aging (Pellicena & Schulman, 2014, pp. 2–3; Yuasa et al., 2018, pp. 3–5). Although KN-93 has not been explicitly used for treating sarcopenia, the mechanistic insights gained from cardiac and neuronal models have prompted proposals for its repurposing. Thus, while its history has been dominated by applications in cardiovascular and cancer research, there is growing experimental evidence that the inhibitory modulation of CaMKII by KN-93 could be leveraged to address muscle wasting pathologies.

Mechanism of Action:
The molecular mechanism of KN-93 centers on its ability to inhibit CaMKII by targeting the Ca2+/calmodulin activation process. CaMKII is a multifunctional serine/threonine kinase that must bind Ca2+-bound calmodulin to transition from an autoinhibited state to an active conformation. KN-93 interferes with this process by binding directly to the Ca2+/calmodulin complex itself, rather than the kinase active site. This binding prevents the necessary displacement of CaMKII’s autoinhibitory regulatory segment, thereby forestalling autophosphorylation at critical residues such as Thr286/287, which are essential for achieving persistent kinase activity (Wong et al., 2019, pp. 18–19; Pellicena & Schulman, 2014, pp. 2–3). By competitively inhibiting the Ca2+/CaM binding step, KN-93 blocks the enzyme’s transition to the active state, resulting in reduced phosphorylation of downstream substrates. One such substrate is the ryanodine receptor 1 (RyR1), a calcium release channel in the sarcoplasmic reticulum of skeletal muscle cells. In aged myotubes, hyperactivation of CaMKII can lead to increased phosphorylation of RyR1, which in turn promotes pathological Ca2+ leak from the sarcoplasmic reticulum (Pellicena & Schulman, 2014, pp. 2–3; Wong et al., 2019, pp. 18–19). This Ca2+ leak contributes directly to muscle weakness and may underlie the physiological deterioration observed in sarcopenia. In vitro biochemical assays have determined that KN-93 exhibits effective inhibitory potency, with low micromolar IC50 values under conditions where Ca2+/CaM is the activating ligand, supporting its use as a reliable and cell-permeable inhibitor (Wong et al., 2019, pp. 14–16; Franchini et al., 2010, pp. 5–6). It is important to note that while KN-93 acts by binding to Ca2+/CaM, there is also evidence that it may exert off-target effects on ion channels such as L-type Ca2+ channels and voltage-gated potassium channels, necessitating the use of inactive analogs like KN-92 in experimental designs to confirm specificity (Pellicena & Schulman, 2014, pp. 3–5; Hegyi et al., 2015).

Expected Effect:
The therapeutic hypothesis for repurposing KN-93 in sarcopenia is based on its capacity to modulate aberrant CaMKII activity that develops with aging. In aged myotubes and skeletal muscle tissue, it is proposed that hyperactive CaMKII leads to pathological phosphorylation of RyR1. Elevated RyR1 phosphorylation increases spontaneous Ca2+ leak from the sarcoplasmic reticulum, depleting stored Ca2+ and disrupting the precise control of Ca2+ transients that are essential for effective muscle contraction. By administering KN-93, it is expected that the compound will reduce RyR1 phosphorylation by selectively inhibiting CaMKII, thus stabilizing calcium homeostasis within muscle cells. In vitro assays should reveal a reduction in the frequency and duration of Ca2+ sparks—localized and transient Ca2+ release events from the sarcoplasmic reticulum—that are typically elevated in aged muscle fibers (Wong et al., 2019, pp. 18–19; Pellicena & Schulman, 2014, pp. 2–3). With a decrease in pathological SR Ca2+ leak, the SR Ca2+ stores should be better preserved, leading to improved amplitude and consistency of evoked Ca2+ transients during electrically stimulated contraction. This restoration of calcium handling would be expected to translate to enhanced contractile function and reduced muscle fatigue, both of which are key factors in countering the clinical manifestations of sarcopenia. Importantly, skeletal muscle has been shown to express CaMKII as well as RyR1, and the link between their dysregulated activity and muscle weakness has been supported by studies in both preclinical skeletal muscle models and denervation-induced atrophy paradigms (Yuasa et al., 2018, pp. 3–5; Pellicena & Schulman, 2014, pp. 2–3). In this context, KN-93’s ability to interfere with the pathway leading to RyR1 hyperphosphorylation represents a direct mechanistic intervention that addresses a molecular hallmark of muscle aging.

Overall Evaluation:
The evaluation of KN-93 as a potential therapeutic candidate for sarcopenia reveals both promising strengths and notable weaknesses. One of the principal strengths of KN-93 is its well-defined mechanism of action. By specifically targeting the Ca2+/calmodulin-dependent activation process of CaMKII, KN-93 directly interferes with a key node that has been implicated in the dysregulation of calcium handling in aging skeletal muscle. This mechanistic rationale is supported by biochemical and cellular studies demonstrating that excessive CaMKII activity leads to increased phosphorylation of RyR1, promoting SR Ca2+ leak and contributing to muscle fatigue and weakness (Wong et al., 2019, pp. 18–19; Pellicena & Schulman, 2014, pp. 2–3). The use of KN-93 in various preclinical models—as observed in cardiac and neuronal studies—provides a strong proof-of-concept that CaMKII inhibition can have beneficial effects on calcium regulation, lending credibility to its repurposing for sarcopenia. In terms of translational feasibility, KN-93 is cell-permeable and has been shown to be effective at low micromolar concentrations in vitro, suggesting that appropriate dosing regimens can be established in subsequent preclinical studies. The compound’s ability to modulate key targets in the CaMKII signaling cascade, coupled with its direct impact on RyR1 phosphorylation, aligns well with the proposed therapeutic hypothesis that preventing SR Ca2+ leak will improve muscle function in aged individuals.

However, there are also several weaknesses and challenges that must be addressed before KN-93 can be considered a strong candidate for clinical development in sarcopenia. First, the clinical history of KN-93 indicates that it has not been evaluated in clinical trials for sarcopenia or muscle wasting conditions. Searches in clinical trial databases have returned no studies using KN-93 in this context, implying that its safety profile and efficacy in human muscle have not been established (ClinicalTrials.gov, n.d.). Second, KN-93 is known to display off-target effects, including inhibition of L-type Ca2+ channels and voltage-gated potassium channels. These off-target activities complicate the interpretation of experimental results and could lead to unintended side effects if not carefully controlled. The use of inactive analogs such as KN-92 in experimental studies is essential to dissect CaMKII-specific effects and to ensure that observed benefits in muscle function are due solely to correction of aberrant CaMKII-RyR1 signaling (Pellicena & Schulman, 2014, pp. 3–5; Hegyi et al., 2015). Third, while KN-93 is effective in in vitro and some preclinical settings, its pharmacokinetic properties in vivo—particularly regarding oral bioavailability and metabolic stability in humans—are relatively underexplored. This lack of data may pose challenges in optimizing dosing regimens and ensuring sustained therapeutic levels in muscle tissue without systemic toxicity.

Despite these concerns, the overall evaluation suggests that KN-93 possesses a compelling mechanistic rationale as a candidate for repurposing in sarcopenia. The expected effect of reducing pathological RyR1 phosphorylation and stabilizing SR Ca2+ stores directly addresses the cellular dysfunction observed in aging muscle. Moreover, the extensive body of preclinical research documenting the role of CaMKII in diseases of cardiac and skeletal muscle provides a strong foundation for further investigation. Future studies should focus on conducting detailed pharmacokinetic and toxicological evaluations of KN-93 in animal models of sarcopenia, as well as exploring targeted delivery methods (such as nanoparticle-based formulations) to enhance tissue specificity and minimize off-target effects. It may also be valuable to compare KN-93 with newer CaMKII inhibitors that have improved selectivity and bioavailability profiles, to determine whether KN-93 represents the optimal candidate for translation or if further optimization is required.

In conclusion, KN-93 offers a promising yet preliminary approach to addressing sarcopenia via inhibition of CaMKII and subsequent correction of RyR1-mediated calcium leak. The strengths of this candidate lie in its well-characterized mechanism of action, its demonstrated efficacy in other disease models where calcium dysregulation is key, and its cell-permeable nature that allows for modulation of intracellular signaling pathways. The primary weaknesses center on its limited clinical evaluation in muscle wasting conditions, potential off-target activities, and the need for more comprehensive in vivo pharmacokinetic data. Overall, while KN-93 is not yet ready for clinical use as a therapy for sarcopenia, its mechanistic profile and preclinical track record justify further investigation, including detailed animal studies and formulation improvements that could ultimately pave the way for its repurposing as a therapeutic agent for muscle degeneration in aging populations (Wong et al., 2019, pp. 1–3; ClinicalTrials.gov, n.d.; Pellicena & Schulman, 2014, pp. 2–3).

References
Beauverger, P., Ozoux, M.-L., Bégis, G., Glénat, V., Briand, V., Philippo, M.-C., Daveu, C., Tavares, G., Roy, S., Corbier, A., Briand, P., Dorchies, O., Bauchet, A.-L., Nicolai, E., Duclos, O., Tamarelle, D., Pruniaux, M.-P., Muslin, A. J., & Janiak, P. (2020). Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvz097

Brzozowski, J. S., & Skelding, K. A. (2019). The multi-functional calcium/calmodulin stimulated protein kinase (CaMK) family: Emerging targets for anti-cancer therapeutic intervention. Pharmaceuticals, 12(1), 8. https://doi.org/10.3390/ph12010008

ClinicalTrials.gov. (n.d.). Search results for “KN-93 OR CaMKII inhibitor AND (sarcopenia OR muscle wasting OR aging OR skeletal muscle)”. Retrieved from https://clinicaltrials.gov

Franchini, C., Bruno, C., Lentini, G., Catalano, A., Carocci, A., Lovece, A., Di Mola, A., Cavalluzzi, M., Tortorella, P., Loiodice, F., Iaccarino, G., Campiglia, P., & Novellino, E. (2010). Microwave-assisted synthesis of KN-93, a potent and selective inhibitor of Ca2+/calmodulin-dependent protein kinase II. Synthesis, 2010, 4193–4198. https://doi.org/10.1055/s-0030-1258298

Hegyi, B., Chen-Izu, Y., Jian, Z., Shimkunas, R., Izu, L. T., & Banyasz, T. (2015). KN-93 inhibits IKr in mammalian cardiomyocytes. Journal of Molecular and Cellular Cardiology, 89, 173–176. https://doi.org/10.1016/j.yjmcc.2015.10.012

Pellicena, P., & Schulman, H. (2014). CaMKII inhibitors: From research tools to therapeutic agents. Frontiers in Pharmacology, 5, 21. https://doi.org/10.3389/fphar.2014.00021

Redondo, R. L., Okuno, H., Spooner, P. A., Frenguelli, B. G., Bito, H., & Morris, R. G. M. (2010). Synaptic tagging and capture: Differential role of distinct calcium/calmodulin kinases in protein synthesis-dependent long-term potentiation. The Journal of Neuroscience, 30(14), 4981–4989. https://doi.org/10.1523/JNEUROSCI.3140-09.2010

Sossalla, S., Fluschnik, N., Schotola, H., Ort, K. R., Neef, S., Schulte, T., Wittköpper, K., Renner, A., Schmitto, J. D., Gummert, J., El-Armouche, A., Hasenfuss, G., & Maier, L. S. (2010). Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circulation Research, 107(10), 1150–1161. https://doi.org/10.1161/CIRCRESAHA.110.220418

Wong, M. H., Samal, A. B., Lee, M., Vlach, J., Novikov, N., Niedziela-Majka, A., Feng, J. Y., Koltun, D. O., Brendza, K. M., Kwon, H. J., Schultz, B. E., Sakowicz, R., Saad, J. S., & Papalia, G. A. (2019). The KN-93 molecule inhibits calcium/calmodulin-dependent protein kinase II (CaMKII) activity by binding to Ca2+/CaM. Journal of Molecular Biology, 431(7), 1440–1459. https://doi.org/10.1016/j.jmb.2019.02.001

Yuasa, K., Okubo, K., Yoda, M., Otsu, K., Ishii, Y., Nakamura, M., Itoh, Y., & Horiuchi, K. (2018). Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy. Scientific Reports, 8, Article 10382. https://doi.org/10.1038/s41598-018-26632-w
